New pain reliever may help combat opioid abuse

Image
IANS New York
Last Updated : Aug 17 2017 | 7:22 PM IST

Scientists have discovered a powerful pain reliever that is effective in alleviating neuropathic pain, a discovery that could be instrumental in addressing the opioid abuse epidemic, one of the biggest public health challenges today.

In the study, the synthetic compound -- known as UKH-1114 -- was found effective in relieving neuropathic pain in injured mice. It was as effective as a drug widely used for pain relief called gabapentin.

The new pain drug binds to a receptor on cells throughout the central nervous system called the sigma 2 receptor.

Administering UKH-1114 on mice with nerve damage showed reduction in pain, but at a much lower dose than gabapentin (one-sixth as much) and was effective much longer (lasting for a couple of days, compared with four to six hours).

"This opens the door to having a new treatment for neuropathic pain that is not an opioid," said Stephen Martin, Professor at The University of Texas at Austin.

"And that has huge implications," Martin added, in the paper published in the journal ACS Chemical Neuroscience.

If the drug is proved to be safe, effective and non-addictive in humans, the discovery could be instrumental in addressing the opioid abuse epidemic, the researchers said.

According to the National Institute on Drug Abuse, nearly two million people in the US suffer from addiction to prescription opioid pain relievers.

Opioids also often require increased dosing to maintain efficacy.

Alternatives to opioids have their own drawbacks -- for example, gabapentin (sold as Neurontin) can cause cognitive impairment in certain individuals, the researchers said.

Neuropathic pain, or chronic pain, is caused when nerves in the central nervous system are damaged. Among other things, it can result from chemotherapy, diabetes and injuries to the brain or spinal cord.

--IANS

rt/him/mr

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 17 2017 | 7:12 PM IST

Next Story